MedTrace Logo

Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)

NCT00412256 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-12-18

No results posted yet for this study

Summary

The primary hypothesis constitutes that the fish-oil preparation (Omegaven) is superior to the preparation based on Soja-oil (Lipovenös)to reduce signs and symptoms in patients with active rheumatoid arthritis.

Conditions

Interventions

DRUG

Omegaven (10% fish-oil emulsion; Fresenius-Kabi)

Sponsors & Collaborators

  • Humanis Klinikum Niederosterreich

    lead OTHER

Principal Investigators

  • Burkhard F Leeb, MD · Center for Rheumatology Lower Austria; Humanisklinikum NÖ

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2006-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00412256 on ClinicalTrials.gov